[1] Vaughn DJ, Brown AW Jr, Harker WC, et al.Multicenter phase II study of estramustine phosphate plus weekly paclitaxel in patientes with androgen-independent prostate carcinoma[J]. Cancer, 2004, 100(4):746-750. [2] 张烁, 郭文彬, 朱梅. 载紫杉醇缓释微球的制备及其体外抑瘤效果的观察[J]. 山东大学学报: 医学版, 2011, 49(12):39-47. [3] 王美清. 紫杉醇的临床毒副作用分析及对策[J]. 中国热带医学, 2007, 7(2):237-239. [4] Ruan G, Feng SS.Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEC-PLA) micro-spheres for controlled release of paclitaxel[J]. Biomaterials, 2003, 24(27):5037-5044. [5] Liu Z, Zhu YY, Li ZY, et al.Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells[J]. Oncol Lett, 2016, 12(5):3944-3948. [6] Tyulyandina A, Harrison D, Yin W, et al. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies[J]. Invest New Drugs, 2016(3). [Epub ahead of print] [7] Ai B, Bie Z, Zhang S, et al.Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment[J]. Am J Cancer Res, 2016, 6(8):1624-1635. [8] Osman MA, Elkady MS, Nasr KE.Weekly Paclitaxel versus three-weekly Paclitaxel in recurrent platinum-resistant epithelialovarian and peritoneal cancers: A phase iii study[J]. Clin Med Insights Oncol, 2016, 10:35-41. [9] Ishiguro K, Zhu YL, Lin ZP, et al.Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines[J]. J Transl Sci, 2016, 2(2):117-124. [10] 余志英, 李丽文, 杜静, 等. 紫杉醇诱导卵巢癌细胞凋亡及细胞周期改变的研究[J]. 中国医师杂志, 2006, 18(3):322-324. |